$LQDA

Moomaw Scott sold $682K of LQDA

Moomaw Scott (Chief Commercial Officer) sold 9,539 shares of Liquidia Corp (LQDA) at an average of $71.51 ($71.39–$71.52, $0.68M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Moomaw Scott
Published Jul 15, 2026, 12:01 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 15, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

Because the sale is pre-arranged under a 10b5-1 plan and lacks any accompanying corporate update, it is unlikely to change the investment thesis on its own.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new fundamental information to drive repricing.

03

What to watch

The article provides sale size and price range but no context on total insider holdings, other concurrent transactions, or whether the plan was modified.

Relevance 4/10Novelty 2/10Timing: Filed July 14 after July 13 insider sale.

Background

The article is an SEC Form 4 insider transaction for Liquidia Corp, reporting an open-market sale by the Chief Commercial Officer.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia CCO Moomaw Scott sold $682,141 of LQDA shares in two open-market trades under a 10b5-1 plan on July 13.

Expected impact

Likely limited near-term impact; any effect is more about signaling than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, and it does not include new company performance, guidance, or regulatory/clinical developments.

Market effects

No clear sector read-through; this is company-specific insider trading with no disclosed operational change.

None.

None.

Counterpoint

Insider selling can sometimes precede negative developments, but this transaction is explicitly under a 10b5-1 plan, reducing interpretive value.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider sale disclosure.

  • Moomaw Scott

    Chief Commercial Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient